Immunovant Inc. (IMVT)
23.79
0.91 (3.98%)
At close: Jan 15, 2025, 11:19 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 231.00K | 1.32M | 1.23M | 998.00K | 21.00K | n/a | n/a |
| Gross Profit | -231.00K | -1.32M | -1.23M | -998.00K | -21.00K | n/a | n/a |
| Operating Income | -282.71M | -198.47M | -156.16M | -107.79M | -65.67M | -450 | -136.74M |
| Interest Income | 24.95M | 7.58M | n/a | n/a | 625.00 | n/a | n/a |
| Pretax Income | -258.77M | -210.95M | -156.81M | -107.79M | -66.29M | -448 | -136.74M |
| Net Income | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -448 | -136.74M |
| Selling & General & Admin | 57.28M | 48.02M | 54.23M | 39.51M | 18.15M | 448.00 | 1.48M |
| Research & Development | 212.93M | 160.26M | 101.81M | 68.60M | 47.93M | 25.73M | 135.26M |
| Other Expenses | 12.50M | -253.00K | -781.00K | 328.00K | 412.00K | n/a | n/a |
| Operating Expenses | 282.71M | 208.28M | 156.03M | 108.12M | 66.08M | 448.00 | 136.74M |
| Interest Expense | n/a | 12.48M | 655.00K | n/a | 625.00K | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -2.69M | n/a |
| Cost & Expenses | 282.71M | 208.28M | 156.03M | 108.12M | 66.08M | 448.00 | 136.74M |
| Income Tax | 567.00K | 9.00K | -84.00K | -358.00K | 97.00K | 19.00K | n/a |
| Shares Outstanding (Basic) | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M | 14.38M | 10.00M |
| Shares Outstanding (Diluted) | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M | 14.38M | 10.00M |
| EPS (Basic) | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | n/a | -13.68 |
| EPS (Diluted) | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | n/a | -13.67 |
| EBITDA | -269.98M | -209.63M | -155.58M | -106.79M | -65.64M | -28.41M | n/a |
| Depreciation & Amortization | 231.00K | 1.32M | 1.23M | 998.00K | 21.00K | 10.00K | 136.74M |